Axsome Therapeutics Stock News

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average rating of Buy from the thirteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month price target among analysts that []

Analysts forecast that Axsome Therapeutics, Inc. (NASDAQ:AXSM) will announce earnings of ($0.99) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Axsome Therapeutics earnings, with the lowest EPS estimate coming in at ($1.13) and the highest estimate coming in at ($0.87). Axsome Therapeutics reported earnings per share of ($0.78) during []

We have more clarity on the FDA-cited deficiencies. These are CMC issues and management thinks are easily addressable.

Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.

Marketwide headwinds pushed this promising biotech stock lower this week.

Marketwide headwinds pushed this promising biotech stock lower this week.

All three of these stocks could rise over 100% once stock-market sentiment falls in line with the opinions of investment-bank analysts.

Goldman Sachs Group Inc. lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 70.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,028 shares of the companys stock after selling 100,662 shares during the period. Goldman Sachs Group Inc. owned []

Both of these companies have potential catalysts on the way.

In the last trading session, 1.03 million shares of the Axsome Therapeutics Inc. (NASDAQ:AXSM) were traded, and its beta was 2.18. Most recently the companys share price was $35.80, and it changed around $0.21 or 0.59% from the last close, which brings the market valuation of the company to $1.34B. AXSM currently trades at a Lets Talk About How Axsome Therapeutics Inc. (NASDAQ: AXSM) Stock Is Doing. Read More »

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie purchased 527 shares of the firms stock in a transaction that occurred on Thursday, November 18th. The stock was acquired at an average price of $35.50 per share, for a total transaction of $18,708.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, []

Man Group plc trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 80.9% during the second quarter, Holdings Channel reports. The firm owned 7,994 shares of the companys stock after selling 33,907 shares during the quarter. Man Group plcs holdings in Axsome Therapeutics were worth $539,000 at the end of the most recent []

Axsome Therapeutics (NASDAQ:AXSM) had its price target reduced by Mizuho from $55.00 to $51.00 in a research note released on Thursday, The Fly reports. They currently have a buy rating on the stock. Several other equities analysts have also recently commented on AXSM. SVB Leerink reduced their target price on Axsome Therapeutics from $75.00 to []

Axsome Therapeutics, Inc. (NASDAQ:AXSM)s stock price traded up 6.6% during mid-day trading on Friday following insider buying activity. The company traded as high as $38.79 and last traded at $37.95. 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. The stock had previously closed at []

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have been assigned an average rating of “Buy” from the thirteen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price target among brokerages […]